• Je něco špatně v tomto záznamu ?

Non-psychotropic cannabinoids as inhibitors of TET1 protein

V. Antonyová, Z. Kejík, T. Brogyanyi, R. Kaplánek, K. Veselá, N. Abramenko, T. Ocelka, M. Masařík, A. Matkowski, J. Gburek, R. Abel, A. Goede, R. Preissner, P. Novotný, M. Jakubek

. 2022 ; 124 (-) : 105793. [pub] 20220406

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22017855

Non-psychotropic cannabinoids (e.g., cannabidiol, cannabinol and cannabigerol) are contained in numerous alimentary and medicinal products. Therefore, predicting and studying their possible side effects, such as changes in DNA methylation, is an important task for assessing the safety of these products. Interference with TET enzymes by chelating ferrous ions can contribute to the altered methylation pattern. All tested cannabinoids displayed a strong affinity for Fe(II) ions. Cannabidiol and cannabinol exhibited potent inhibitory activities (IC50 = 4.8 and 6.27 μM, respectively) towards the TET1 protein, whereas cannabigerol had no effect on the enzyme activity. An in silico molecular docking study revealed marked binding potential within the catalytic cavity for CBD/CBN, but some affinity was also found for CBG, thus the total lack of activity remains unexplained. These results imply that cannabinoids could affect the activity of the TET1 protein not only due to their affinity for Fe(II) but also due to other types of interactions (e.g., hydrophobic interactions and hydrogen bonding).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017855
003      
CZ-PrNML
005      
20220804134426.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bioorg.2022.105793 $2 doi
035    __
$a (PubMed)35462234
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Antonyová, Veronika $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic
245    10
$a Non-psychotropic cannabinoids as inhibitors of TET1 protein / $c V. Antonyová, Z. Kejík, T. Brogyanyi, R. Kaplánek, K. Veselá, N. Abramenko, T. Ocelka, M. Masařík, A. Matkowski, J. Gburek, R. Abel, A. Goede, R. Preissner, P. Novotný, M. Jakubek
520    9_
$a Non-psychotropic cannabinoids (e.g., cannabidiol, cannabinol and cannabigerol) are contained in numerous alimentary and medicinal products. Therefore, predicting and studying their possible side effects, such as changes in DNA methylation, is an important task for assessing the safety of these products. Interference with TET enzymes by chelating ferrous ions can contribute to the altered methylation pattern. All tested cannabinoids displayed a strong affinity for Fe(II) ions. Cannabidiol and cannabinol exhibited potent inhibitory activities (IC50 = 4.8 and 6.27 μM, respectively) towards the TET1 protein, whereas cannabigerol had no effect on the enzyme activity. An in silico molecular docking study revealed marked binding potential within the catalytic cavity for CBD/CBN, but some affinity was also found for CBG, thus the total lack of activity remains unexplained. These results imply that cannabinoids could affect the activity of the TET1 protein not only due to their affinity for Fe(II) but also due to other types of interactions (e.g., hydrophobic interactions and hydrogen bonding).
650    12
$a kanabidiol $x chemie $x farmakologie $7 D002185
650    12
$a kanabinoidy $x farmakologie $7 D002186
650    _2
$a kanabinol $x farmakologie $7 D002187
650    12
$a Cannabis $x chemie $7 D002188
650    _2
$a železnaté sloučeniny $7 D005296
650    _2
$a simulace molekulového dockingu $7 D062105
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kejík, Zdeněk $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry and Technology, Technická 5, 166 28 Prague, Czech Republic
700    1_
$a Brogyanyi, Tereza $u BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague, Czech Republic
700    1_
$a Kaplánek, Robert $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry and Technology, Technická 5, 166 28 Prague, Czech Republic
700    1_
$a Veselá, Kateřina $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry and Technology, Technická 5, 166 28 Prague, Czech Republic
700    1_
$a Abramenko, Nikita $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic
700    1_
$a Ocelka, Tomáš $u CannabiLab, GMP Testing and Production Facility, E&H Services, Inc., Dobra 240, 73951, Czech Republic
700    1_
$a Masařík, Michal $u Department of Physiology and Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 8 CZ-625 00 Brno, Czech Republic
700    1_
$a Matkowski, Adam $u Department of Pharmaceutical Biology and Biotechnology, Wroclaw Medical University, Borowska 211, 50556 Wroclaw, Poland
700    1_
$a Gburek, Jakub $u Department of Pharmaceutical Biochemistry, Wroclaw Medical University, Borowska 211A, 50556 Wroclaw, Poland
700    1_
$a Abel, Renata $u Department of Pharmaceutical Biology and Biotechnology, Wroclaw Medical University, Borowska 211, 50556 Wroclaw, Poland; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, Philippstrasse 12, Berlin, Germany
700    1_
$a Goede, Andrean $u Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, Philippstrasse 12, Berlin, Germany
700    1_
$a Preissner, Robert $u Science-IT and Institute of Physiology, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Philippstrasse 12, 10115, Berlin, Germany
700    1_
$a Novotný, Petr $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic
700    1_
$a Jakubek, Milan $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic; BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry and Technology, Technická 5, 166 28 Prague, Czech Republic. Electronic address: milan.jakubek@lf1.cuni.cz
773    0_
$w MED00000771 $t Bioorganic chemistry $x 1090-2120 $g Roč. 124, č. - (2022), s. 105793
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35462234 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134420 $b ABA008
999    __
$a ok $b bmc $g 1821783 $s 1169098
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 124 $c - $d 105793 $e 20220406 $i 1090-2120 $m Bioorganic chemistry $n Bioorg Chem $x MED00000771
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace